Koninklijke Philips (NYSE:PHG) Shares Gap Up to $20.06

Koninklijke Philips (NYSE:PHG - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $20.06, but opened at $20.66. Koninklijke Philips shares last traded at $20.69, with a volume of 104,334 shares trading hands.

Wall Street Analyst Weigh In

PHG has been the subject of several recent analyst reports. BNP Paribas cut shares of Koninklijke Philips from an "outperform" rating to an "underperform" rating in a report on Wednesday, February 7th. StockNews.com raised shares of Koninklijke Philips from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $19.00.

Koninklijke Philips Price Performance

The business's 50 day moving average price is $20.42 and its 200 day moving average price is $20.86. The stock has a market capitalization of $18.95 billion, a P/E ratio of -35.81, a price-to-earnings-growth ratio of 1.04 and a beta of 0.88. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.20 and a quick ratio of 0.78.

Koninklijke Philips (NYSE:PHG - Get Free Report) last announced its quarterly earnings results on Monday, January 29th. The technology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. Koninklijke Philips had a negative net margin of 2.53% and a positive return on equity of 14.17%. The firm had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.47 billion. Sell-side analysts forecast that Koninklijke Philips will post 1.52 EPS for the current year.

Institutional Trading of Koninklijke Philips

Several large investors have recently added to or reduced their stakes in PHG. Raymond James Financial Services Advisors Inc. grew its position in Koninklijke Philips by 4.9% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 16,411 shares of the technology company's stock valued at $501,000 after buying an additional 771 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Koninklijke Philips by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 62,767 shares of the technology company's stock worth $1,916,000 after purchasing an additional 1,414 shares during the period. Cetera Advisor Networks LLC bought a new position in shares of Koninklijke Philips in the first quarter worth approximately $311,000. Citigroup Inc. boosted its position in shares of Koninklijke Philips by 1.3% in the first quarter. Citigroup Inc. now owns 36,882 shares of the technology company's stock worth $1,126,000 after purchasing an additional 483 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of Koninklijke Philips by 9.9% in the first quarter. Bank of Montreal Can now owns 94,798 shares of the technology company's stock worth $3,002,000 after purchasing an additional 8,515 shares during the period. 13.67% of the stock is currently owned by institutional investors.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.